摘要
【目的】研究药物洗脱球囊（DEB）用于治疗冠心病患者经皮冠脉介入术（PCI）术后支架内再狭窄（ISR）的临床效果。【方法】回顾性分析2012年1月至2017年5月本院收治的因IsR就诊的50例冠心病患者的临床资料，根据支架类型的不同将其分为DES组和DEB组。比较两组患者临床基本特征、治疗前后冠脉造影特点，随访治疗后12个月内患者发生终点事件的情况。【结果】治疗6个月后冠脉造影结果显示，DEB组再狭窄发生率显著低于DES组，差异具有统计学意义（P〈0．05）；两组TIMI血流I级、Ⅱ级、Ⅲ级，血管狭窄程度，支架内及节段内最小管腔直径、晚期管腔丢失比较，差异均无统计学意义（P〉0．05）。DES组支架内二次狭窄发生率为24．00％（6／25）显著高于DEB组的4．00％（1／25），差异具有统计学意义（χ2-4．153，P=0．042〈0．05）。应用Kaplan-Meier生存分析发现，两组患者术后12个月内无MACE生存率比较，差异无统计学意义（P=0．467，P=0．494〉0．05）。【结论】DEB治疗ISR的临床效果与DES相当，且未造成如动脉撕裂夹层等严重并发症，安全性较高。
[Objective]To study the clinical effect of drug-eluting balloon （DEB） in the treatment of ISR after percutaneous coronary intervention （PCI） in patients with coronary heart disease.[Methods]The clinical data of 50 pa tients with coronary heart disease treated by ISR from January 2012 to May 2017 were analyzed retrospectively. Ac cording to the type of stent, it was divided into DES group and DEB group. The clinical features, coronary angiogra- phy features, and terminal events within 12 months after treatment were compared between the two groups.[Results] After 6 months of treatment, coronary angiography showed that the incidence of restenosis in the DEB group was sig- nificantly lower than that in the DES group （ P 〈0.05）.There was no significant difference in TIMI blood flow grade I, II, III, stenosis degree, minimum lumen diameter and late lumen loss between the two groups （ P 〉0.05）. The incidence of secondary stent stenosis in the DES group was 24.00% （6 / 25）, which was significantly higher than that in the DEB group （4.000//0, 1 / 25）. The difference was statistically significant（χ2 =4.153, P =0.042〈0.05）. Kap- lan-Meier survival analysis showed that there was no significant difference in MACE free survival rate between the two groups within 12 months after operation （χ2 =0.467, P =0.494〉0.05）. [ConclusionlThe clinical efficacy of DEB in the treatment of ISR is comparable to that of DES with high safety, and no serious complications such as artery lacer- ation dissection have been caused.
作者
邹永伟
胡小恋
ZOU Yong-wei;HU Xiao-lian(The Second People＇s Hospital of Hainan,Wuzhishan,Hainan Province,57229)
出处
《医学临床研究》
CAS
2018年第10期1899-1901,共3页
Journal of Clinical Research
